Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tsekov

Showing results (121-130 of 123) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 123 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancerMary E R O'Brien, Tudor-Eliade Ciuleanu, Hristo Tsekov, et al.
Folia Medica|September 9, 2000
Treatment of immune nephropathies with high doses of immunoglobulinsD G Nikolov, S M Pandeva, E P Kumchev, et al.
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
Pageof 13

Showing results (121-130 of 123) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 123 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2006
Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancerMary E R O'Brien, Tudor-Eliade Ciuleanu, Hristo Tsekov, et al.
Folia Medica|September 9, 2000
Treatment of immune nephropathies with high doses of immunoglobulinsD G Nikolov, S M Pandeva, E P Kumchev, et al.
Anti-Cancer Drugs|August 13, 2005
Bendamustine prolongs progression-free survival in metastatic breast cancer (MBC): a phase III prospective, randomized, multicenter trial of bendamustine hydrochloride, methotrexate and 5-fluorouracil (BMF) versus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) as first-line treatment of MBCG von Minckwitz, I Chernozemsky, L Sirakova, et al.
Pageof 13